Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lantern Pharma Inc.

3.32
-0.1100-3.21%
Post-market: 3.13-0.1893-5.70%19:31 EDT
Volume:61.19K
Turnover:204.07K
Market Cap:35.81M
PE:-1.80
High:3.43
Open:3.28
Low:3.25
Close:3.43
Loading ...

Leslie W. Kreis, 10% Owner, Reports Disposal of Lantern Pharma Inc. Common Shares

Reuters
·
30 May

Lantern Pharma Announces Promising Preclinical Data for LP-184 in Pediatric Brain Cancer, Plans Phase I Clinical Trial for Late 2025

Reuters
·
29 May

Lantern Pharma's Lp-184 Shows Promising in Vivo Activity in Atypical Teratoid Rhabdoid Tumors (Atrt) at Sno Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials

THOMSON REUTERS
·
29 May

Lantern Pharma Advances AI-Driven Cancer Therapies

TIPRANKS
·
16 May

Lantern Pharma Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
15 May

Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

THOMSON REUTERS
·
15 May

Lantern Pharma Q1 Net Income USD -4.5 Million

THOMSON REUTERS
·
15 May

Press Release: Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

Dow Jones
·
15 May

Lantern Pharma Reports Q1 2025 Results: R&D Expenses Down to $3.3M, Cash Reserves at $19.7M

Reuters
·
15 May

Lantern Pharma Q1 EPS $(0.42) Beats $(0.49) Estimate

Benzinga
·
15 May

Lantern Pharma Inc: Qtrly Shr Loss $0.42

THOMSON REUTERS
·
15 May

Lantern Pharma Inc expected to post a loss of 49 cents a share - Earnings Preview

Reuters
·
13 May

Press Release: Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET

Dow Jones
·
08 May

Lantern Advances Drug Candidate Lp-184 With Ind Clearance for Phase 1B/2 Clinical Trial in Triple Negative Breast Cancer (Tnbc)

THOMSON REUTERS
·
05 May

Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)

Business Wire
·
05 May

EXCLUSIVE: Lantern Advances Breast Cancer Drug Candidate With FDA Clearance For Early-Stage Trial

Benzinga
·
05 May

Lantern Pharma Inc expected to post a loss of 49 cents a share - Earnings Preview

Reuters
·
05 May

Lantern Pharma initiated with a Buy at Lake Street

TIPRANKS
·
02 Apr

LTRN: 2024 Financial Results

Zacks Small Cap Research
·
28 Mar

Lantern Pharma Inc Qtrly EPS $-0.54

Reuters
·
28 Mar